Abstract
Fucosylation is an important type of glycosylation involved in cancer, and fucosylated proteins could be employed as cancer biomarkers. Previously, we reported that fucosylated N-glycans on haptoglobin in the sera of patients with pancreatic cancer were increased by lectin-ELISA and mass spectrometry analyses. However, an increase in fucosylated haptoglobin has been reported in various types of cancer. To ascertain if characteristic fucosylation is observed in each cancer type, we undertook site-specific analyses of N-glycans on haptoglobin in the sera of patients with five types of operable gastroenterological cancer (esophageal, gastric, colon, gallbladder, pancreatic), a non-gastroenterological cancer (prostate cancer) and normal controls using ODS column LC-ESI MS. Haptoglobin has four potential glycosylation sites (Asn184, Asn207, Asn211, Asn241). In all cancer samples, monofucosylated N-glycans were significantly increased at all glycosylation sites. Moreover, difucosylated N-glycans were detected at Asn 184, Asn207 and Asn241 only in cancer samples. Remarkable differences in N-glycan structure among cancer types were not observed. We next analyzed N-glycan alditols released from haptoglobin using graphitized carbon column LC-ESI MS to identify the linkage of fucosylation. Lewis-type and core-type fucosylated N-glycans were increased in gastroenterological cancer samples, but only core-type fucosylated N-glycan was relatively increased in prostate cancer samples. In metastatic prostate cancer, Lewis-type fucosylated N-glycan was also increased. These data suggest that the original tissue/cell producing fucosylated haptoglobin is different in each cancer type and linkage of fucosylation might be a clue of primary lesion, thereby enabling a differential diagnosis between gastroenterological cancers and non-gastroenterological cancers.






Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.Abbreviations
- LC-ESI MS:
-
Liquid chromatography-electrospray ionization-mass spectrometry
- Hpt:
-
Haptoglobin
- NV:
-
Normal volunteers
- Eso:
-
Esophageal cancer
- Gas:
-
Gastric cancer
- Col:
-
Colon cancer
- Pan:
-
Pancreatic cancer
- Gal:
-
Gallbladder cancer
- Pro:
-
Prostate cancer
References
Becker, D.J., Lowe, J.B.: Fucose: biosynthesis and biological function in mammals. Glycobiology 13, 41R–53R (2003)
Hakomori, S.: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigen. Adv. Cancer Res. 52, 257–331 (1989)
Miyoshi, E., Moriwaki, K., Nakagawa, T.: Biological function of fucosylation in cancer biology. J. Biochem. 143, 725–729 (2008)
Dempsey, E., Rudd, P.M.: Acute phase glycoproteins: bystanders or participants in carcinogenesis? Ann. N. Y. Acad. Sci. 1253, 122–132 (2012)
Okuyama, N., Ide, Y., Nakano, M., Nakagawa, T., Yamanaka, K., Moriwaki, K., Murata, K., Ohigashi, H., Yokoyama, S., Eguchi, H., Ishikawa, O., Ito, T., Kato, M., Kasahara, S., Gu, J., Taniguchi, N., Miyoshi, E.: Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int. J. Cancer 118, 2803–2808 (2006)
Nakano, M., Nakagawa, T., Ito, T., Kitada, T., Hijioka, T., Kasahara, A., Tajiri, M., Wada, Y., Taniguchi, N., Miyoshi, E.: Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int. J. Cancer 122, 2301–2309 (2008)
Black, J.A., Chan, G.F., Hew, C.L., Dixon, G.H.: Gene action in the human haptoglobins. III. Isolation of the α-chains as single gene products. Isolation, molecular weight, and amino acid composition of α and β chains. Can. J. Biochem. 48, 123–132 (1970)
Kurosky, A., Barnett, D.R., Lee, T.H., Touchstone, B., Hay, R.E., Arnott, M.S., Bowman, B.H., Fitch, W.M.: Covalent structure of human haptoglobin: a serine protease homolog. Proc. Natl. Acad. Sci. U. S. A. 77, 3388–3392 (1980)
Ferens-Sieczkowska, M., Olczak, M.: Carbohydrate structures of haptoglobin in sera of healthy people and a patient with congenital disorder of glycosylation. Z. Naturforsch. C 56, 122–131 (2001)
He, Z., Aristoteli, L.P., Kritharides, L., Garner, B.: HPLC analysis of discrete haptoglobin isoform N-linked oligosaccharides following 2D-PAGE isolation. Biochem. Biophys. Res. Commun. 343, 496–503 (2006)
Noda, K., Miyoshi, E., Gu, J., Gao, C.X., Nakahara, S., Kitada, T., Honke, K., Suzuki, K., Yoshihara, H., Yoshikawa, K., Kawano, K., Tonetti, M., Kasahara, A., Hori, M., Hayashi, N., Taniguchi, N.: Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res. 63, 6282–6289 (2003)
Ang, I.L., Poon, T.C., Lai, P.B., Chan, A.T., Ngai, S.M., Hui, A.Y., Johnson, P.J., Sung, J.J.: Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J. Proteome Res. 5, 2691–700 (2006)
Zhang, S., Shu, H., Luo, K., Kang, X., Zhang, Y., Lu, H., Liu, Y.: N-linked glycan changes of serum haptoglobin β chain in liver disease patients. Mol. Biosyst. 7, 1621–1628 (2011)
Zhang, S., Jiang, K., Sun, C., Lu, H., Liu, Y.: Quantitative analysis of site-specific N-glycans on sera haptoglobin β chain in liver diseases. Acta Biochim Biophys Sin (Shanghai) 45, 1021–1029 (2013)
Zhu, J., Lin, Z., Wu, J., Yin, H., Dai, J., Feng, Z., Marrero, J., Lubman, D.M.: Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J. Proteome Res. 13, 2986–2997 (2014)
Hoagland, L.F., Campa, M.J., Gottlin, E.B., Herndon, J.E., Patz, E.F.: Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 110, 2260–2268 (2007)
Arnold, J.N., Saldova, R., Hamid, U.M., Rudd, P.M.: Evaluation of the serum N-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics 8, 3284–3293 (2008)
Tsai, H.Y., Boonyapranai, K., Sriyam, S., Yu, C.J., Wu, S.W., Khoo, K.H., Phutrakul, S., Chen, S.T.: Glycoproteomics analysis to identify a glycoform on haptoglobin associated with lung cancer. Proteomics 11, 2162–2170 (2011)
Váradi, C., Mittermayr, S., Szekrényes, Á., Kádas, J., Takacs, L., Kurucz, I., Guttman, A.: Analysis of haptoglobin N-glycome alterations in inflammatory and malignant lung diseases by capillary electrophoresis. Electrophoresis 34, 2287–2294 (2013)
Zhao, J., Patwa, T.H., Qiu, W., Shedden, K., Hinderer, R., Misek, D.E., Anderson, M.A., Simeone, D.M., Lubman, D.M.: Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J. Proteome Res. 6, 1864–61874 (2007)
Matsumoto, H., Shinzaki, S., Narisada, M., Kawamoto, S., Kuwamoto, K., Moriwaki, K., Kanke, F., Satomura, S., Kumada, T., Miyoshi, E.: Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin. Chem. Lab. Med. 48, 505–512 (2010)
Lin, Z., Simeone, D.M., Anderson, M.A., Brand, R.E., Xie, X., Shedden, K.A., Ruffin, M.T., Lubman, D.M.: Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J. Proteome Res. 10, 2602–2611 (2011)
Sarrats, A., Saldova, R., Pla, E., Fort, E., Harvey, D.J., Struwe, W.B., de Llorens, R., Rudd, P.M., Peracaula, R.: Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin. Appl. 4, 432–448 (2010)
Park, S.Y., Lee, S.H., Kawasaki, N., Itoh, S., Kang, K., Hee Ryu, S., Hashii, N., Kim, J.M., Kim, J.Y., Hoe Kim, J.: α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers. Int. J. Cancer 130, 2366–2376 (2012)
Takeda, Y., Shinzaki, S., Okudo, K., Moriwaki, K., Murata, K., Miyoshi, E.: Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 118, 3036–3043 (2012)
Bones, J., Byrne, J.C., O’Donoghue, N., McManus, C., Scaife, C., Boissin, H., Nastase, A., Rudd, P.M.: Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J. Proteome Res. 10, 1246–1265 (2011)
Thompson, S., Dargan, E., Turner, G.A.: Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer. Cancer Lett. 66, 43–48 (1992)
Turner, G.A., Goodarzi, M.T., Thompson, S.: Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Glycoconj. J. 12, 211–218 (1995)
Saldova, R., Royle, L., Radcliffe, C.M., Abd Hamid, U.M., Evans, R., Arnold, J.N., Banks, R.E., Hutson, R., Harvey, D.J., Antrobus, R., Petrescu, S.M., Dwek, R.A., Rudd, P.M.: Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17, 1344–1356 (2007)
Fujimura, T., Shinohara, Y., Tissot, B., Pang, P.C., Kurogochi, M., Saito, S., Arai, Y., Sadilek, M., Murayama, K., Dell, A., Nishimura, S., Hakomori, S.: Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int. J. Cancer 122, 39–49 (2008)
Yoon, S.J., Park, S.Y., Pang, P.C., Gallagher, J., Gottesman, J.E., Dell, A., Kim, J.H., Hakomori, S.: N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. Int. J. Oncol. 36, 193–203 (2010)
Kazuno, S., Fujimura, T., Arai, T., Ueno, T., Nagao, K., Fujime, M., Murayama, K.: Multi-sequential surface plasmon resonance analysis of haptoglobin-lectin complex in sera of patients with malignant and benign prostate diseases. Anal. Biochem. 419, 241–249 (2011)
Abbott, K.L., Aoki, K., Lim, J.M., Porterfield, M., Johnson, R., O’Regan, R.M., Wells, L., Tiemeyer, M., Pierce, M.: Targeted glycoproteomic identification of biomarkers for human breast carcinoma. J. Proteome Res. 7, 1470–1480 (2008)
Abd Hamid, U.M., Royle, L., Saldova, R., Radcliffe, C.M., Harvey, D.J., Storr, S.J., Pardo, M., Antrobus, R., Chapman, C.J., Zitzmann, N., Robertson, J.F., Dwek, R.A., Rudd, P.M.: A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 18, 1105–1118 (2008)
Wada, Y., Tajiri, M., Yoshida, S.: Hydrophilic affinity isolation and MALDI multiple-stage tandem mass spectrometry of glycopeptides for glycoproteomics. Anal. Chem. 76, 6560–6565 (2004)
Wilson, N.L., Schulz, B.L., Karlsson, N.G., Packer, N.H.: Sequential analysis of N- and O-linked glycosylation of 2D-PAGE separated glycoproteins. J. Proteome Res. 1, 521–529 (2002)
Nakano, M., Saldanha, R., Göbel, A., Kavallaris, M., Packer, N.H.: Identification of glycan structure alterations on cell membrane proteins in desoxyepothilone B resistant leukemia cells. Mol. Cell. Proteomics (2011). doi:10.1074/mcp.M111.009001
Nakagawa, T., Uozumi, N., Nakano, M., Mizuno-Horikawa, Y., Okuyama, N., Taguchi, T., Gu, J., Kondo, A., Taniguchi, N., Miyoshi, E.: Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J. Biol. Chem. 281, 29797–29806 (2006)
Kaneko, M., Kudo, T., Iwasaki, H., Ikehara, Y., Nishihara, S., Nakagawa, S., Sasaki, K., Shiina, T., Inoko, H., Saitou, N., Narimatsu, H.: Alpha1,3-fucosyltransferase IX (Fuc-TIX) is very highly conserved between human and mouse; molecular cloning, characterization and tissue distribution of human Fuc-TIX. FEBS Lett. 452, 237–242 (1999)
Comelli, E.M., Head, S.R., Gilmartin, T., Whisenant, T., Haslam, S.M., North, S.J., Wong, N.K., Kudo, T., Narimatsu, H., Esko, J.D., Drickamer, K., Dell, A., Paulson, J.C.: A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology 16, 117–131 (2006)
Fujita, K., Shimomura, M., Uemura, M., Nakata, W., Sato, M., Nagahara, A., Nakai, Y., Takamatsu, S., Miyoshi, E.: Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-gleason prostate cancer. Prostate 74, 1052–1058 (2014)
Barthel, S.R., Wiese, G.K., Cho, J., Opperman, M.J., Hays, D.L., Siddiqui, J., Pienta, K.J., Furie, B., Dimitroff, C.J.: Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc. Natl. Acad. Sci. U. S. A. 106, 19491–19496 (2009)
Li, J., Guillebon, A.D., Hsu, J.W., Barthel, S.R., Dimitroff, C.J., Lee, Y.F., King, M.R.: Human fucosyltransferase 6 enables prostate cancer metastasis to bone. Br. J. Cancer 109, 3014–3022 (2013)
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 335 kb)
Rights and permissions
About this article
Cite this article
Takahashi, S., Sugiyama, T., Shimomura, M. et al. Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer. Glycoconj J 33, 471–482 (2016). https://doi.org/10.1007/s10719-016-9653-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10719-016-9653-7
Keywords
Profiles
- Kazutoshi Fujita View author profile